speb/financial-data huggingface dataset:
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Net PPE Purchase And Sale: -85914900000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Net Tangible Assets: 415980400000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 415980400000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Revenue: 1551500000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Revenue: 1551500000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Assets: 43700000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 43700000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Liabilities: 24328500000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 24328500000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Non Current Prepaid Assets: 19604100000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Non Current Prepaid Assets: 19604100000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Normalized EBITDA: 84584200000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 24454700000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Normalized Income: 41658987670.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Normalized Income: 9282269818.28
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Operating Cash Flow: 22373500000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Operating Income: 36802400000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Operating Income: 11736000000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Operating Revenue: 336540700000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Operating Revenue: 98944100000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Ordinary Shares Number: 2463123478.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 2463123478.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Other Cash Adjustment Outside Changein Cash: 24200000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Other Current Assets: 404800000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 404800000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Other Current Liabilities: 9919600000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 9919600000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Other Equity Interest: 127000000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Other Equity Interest: 127000000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Other Intangible Assets: 10380500000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 10380500000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Other Inventories: 18836800000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Other Inventories: 18836800000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Other Non Cash Items: -22226000000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Other Non Current Assets: 31959500000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 31959500000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Other Non Current Liabilities: 1551500000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 1551500000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Other Non Operating Income Expenses: 406400000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 5732600000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Other Operating Expenses: 100286400000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 35946900000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Other Payable: 46822200000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Other Payable: 46822200000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Other Properties: 261447900000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Other Properties: 261447900000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Other Receivables: 17873400000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Other Receivables: 17873400000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Other Short Term Investments: 29299700000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 29299700000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Other Special Charges: -2216000000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Other Special Charges: -3420100000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Payables: 104419000000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Payables: 104419000000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 550900000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 550900000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Prepaid Assets: 25711500000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 25711500000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Pretax Income: 61036700000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Pretax Income: 18720600000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Properties: 43855900000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Properties: 43855900000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Provisionand Write Offof Assets: 175600000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Purchase Of Business: -43113000000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Purchase Of Investment: -49515700000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Purchase Of PPE: -86870500000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Raw Materials: 13253800000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Raw Materials: 13253800000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Reconciled Cost Of Revenue: 83792600000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 18268300000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Reconciled Depreciation: 22970400000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 6938500000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Rent And Landing Fees: 1435600000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Rent Expense Supplemental: 1435600000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Repayment Of Debt: -11808300000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Restricted Cash: 463700000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 463700000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Restructuring And Mergern Acquisition: 0.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Retained Earnings: 146587200000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 146587200000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Sale Of Business: 625600000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Sale Of Investment: 92589000000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Sale Of PPE: 955600000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Selling And Marketing Expense: 89659400000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Selling And Marketing Expense: 23361200000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Selling General And Administration: 92585300000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Selling General And Administration: 23361200000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Share Issued: 2463123478.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Share Issued: 2463123478.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Special Income Charges: 143200000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Special Income Charges: 1347300000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Stockholders Equity: 535789200000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 535789200000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Tangible Book Value: 415980400000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 415980400000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Tax Effect Of Unusual Items: 210287670.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 374669818.28
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Tax Provision: 8095900000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Tax Provision: 5206000000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Tax Rate For Calcs: 0.13
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.28
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Taxes Receivable: 11789400000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Taxes Receivable: 11789400000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Taxes Refund Paid: -3801800000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Total Assets: 811063600000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Total Assets: 811063600000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Total Capitalization: 535933100000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 535933100000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Total Debt: 7885000000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Total Debt: 7885000000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Total Equity Gross Minority Interest: 639470900000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 639470900000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Total Expenses: 299738300000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Total Expenses: 87208100000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Total Liabilities Net Minority Interest: 171592700000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 171592700000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Total Non Current Assets: 616704800000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 616704800000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 33140100000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 33140100000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Total Tax Payable: 27209600000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 27209600000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Total Unusual Items: 1582300000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items: 1347300000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Total Unusual Items Excluding Goodwill: 1582300000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: 1347300000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Work In Process: 6065100000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Work In Process: 6065100000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Working Capital: 55906200000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Working Capital: 55906200000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Write Off: 2072800000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — +Operating Expense: 76201300000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — +Total Revenue: 102441100000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Basic Average Shares: 2462125000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Basic EPS: 3.20
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 15244600000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 8615700000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 8615700000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 2462125000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Diluted EPS: 3.20
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 7878800000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — EBIT: 13997700000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — EBITDA: 22613400000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Gross Profit: 87196500000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Impairment Of Capital Assets: 0.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Interest Expense: 671400000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 671400000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Minority Interests: -1817800000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Net Income: 7878800000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 7878800000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 9696600000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 7878800000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 7878800000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 9696600000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Net Interest Income: -671400000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -671400000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 22213400000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Normalized Income: 7587748470.32
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Operating Income: 10995200000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Operating Revenue: 102441100000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 2560900000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 39632500000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Other Special Charges: -400000000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Pretax Income: 13326300000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 15244600000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 8615700000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Selling And Marketing Expense: 24225300000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Selling General And Administration: 24225300000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Special Income Charges: 400000000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 108948470.32
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Tax Provision: 3629700000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.27
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Total Expenses: 91445900000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items: 400000000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: 400000000.00
AMBUJACEM.NS income_statement (quarterly, 2025-06-30) — Write Off: 0.00
AMBUJACEM.NS income_statement (quarterly, 2025-09-30) — Impairment Of Capital Assets: 0.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — +Operating Expense: 78816000000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — +Total Revenue: 101805200000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 2484146341.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Basic EPS: 0.82
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 19048800000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 9590300000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 9590300000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 2484146341.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Diluted EPS: 0.82
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 2037000000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — EBIT: 4712600000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — EBITDA: 14302900000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Gross Profit: 82756400000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Impairment Of Capital Assets: 0.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Interest Expense: 588500000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 588500000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Minority Interests: -1632700000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Net Income: 2037000000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 2037000000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 3669700000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 2037000000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 2037000000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 3669700000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -588500000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -588500000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 14455200000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Normalized Income: 2172519339.98
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Operating Income: 3940400000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 101805200000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 873200000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 42721200000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Other Special Charges: 152300000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Pretax Income: 4124100000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 19048800000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 9590300000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Selling And Marketing Expense: 23627000000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Selling General And Administration: 23627000000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Special Income Charges: -152300000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: -16780660.02
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Tax Provision: 454400000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.11
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 97864800000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items: -152300000.00
AMBUJACEM.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -152300000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — +Operating Expense: 277657400000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 84768500000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — +Total Revenue: 399694000000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 108916800000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 41850300000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 41850300000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 18684700000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 18684700000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Accumulated Depreciation: -150209800000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Accumulated Depreciation: -150209800000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Additional Paid In Capital: 329168100000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 329168100000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -1156300000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -1156300000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Amortization: 6066000000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Amortization Cash Flow: 6066000000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Available For Sale Securities: 476800000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 476800000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Basic Average Shares: 2468891697.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 2469838057.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Basic EPS: 19.15
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Basic EPS: 7.41
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 50946500000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Buildings And Improvements: 65002800000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Buildings And Improvements: 65002800000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -63443300000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Capital Lease Obligations: 8131500000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 8131500000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 4943600000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 4943600000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 8915900000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 8915900000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 9239500000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 9239500000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Cash Dividends Paid: -4918000000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Cash Equivalents: 1385200000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Cash Equivalents: 1385200000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Cash Financial: 7530700000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Cash Financial: 7530700000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Change In Inventory: -92600000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Change In Other Current Assets: -12451900000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Change In Other Current Liabilities: -12079200000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Change In Payable: 6650000000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Change In Receivables: -213700000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: -18476200000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Changes In Cash: -42030600000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Common Stock: 4943600000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 4943600000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 593473200000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 593473200000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Common Stock Issuance: 0.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Construction In Progress: 101241900000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 101241900000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 91097700000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 20046500000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Current Assets: 137159300000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 137159300000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Current Capital Lease Obligation: 1915200000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 1915200000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Current Debt: 79900000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Current Debt: 79900000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 1995100000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 1995100000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 130962400000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 130962400000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 2590400000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 2590400000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Depreciation: 29638100000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 35704100000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 35704100000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 10527300000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 29638100000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 10527300000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Diluted Average Shares: 2482207686.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 2483242877.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Diluted EPS: 19.05
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: 7.37
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 47281800000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 18301500000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Dividends Payable: 430600000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Dividends Payable: 430600000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Dividends Received Cfi: 68900000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — EBIT: 35223800000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — EBIT: 5489300000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — EBITDA: 70927900000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — EBITDA: 16016600000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — End Cash Position: 8915900000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 354400000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 354400000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: -16294000000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Finished Goods: 5637500000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Finished Goods: 5637500000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: -9828000000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Gain Loss On Investment Securities: -1609000000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Gain Loss On Sale Of PPE: 379400000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — General And Administrative Expense: 2975400000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Goodwill: 135455200000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Goodwill: 135455200000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Goodwill And Other Intangible Assets: 146723200000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 146723200000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Gross Accounts Receivable: 19841000000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Gross Accounts Receivable: 19841000000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Gross PPE: 687719100000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 687719100000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Gross Profit: 308596300000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 88870300000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Hedging Assets Current: 886400000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Hedging Assets Current: 886400000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Held To Maturity Securities: 41200000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Held To Maturity Securities: 41200000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Impairment Of Capital Assets: 0.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Impairment Of Capital Assets: 0.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Interest Expense: 2236100000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Interest Expense: 208000000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Interest Expense Non Operating: 2236100000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 208000000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Interest Income: 5367500000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Interest Income Non Operating: 5367500000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Interest Paid Cff: -1523100000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Interest Received Cfi: 3260200000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Inventory: 45523300000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Inventory: 45523300000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Invested Capital: 594001000000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Invested Capital: 594001000000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Investing Cash Flow: -79351900000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Investmentin Financial Assets: 872400000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 872400000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Issuance Of Capital Stock: 0.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Issuance Of Debt: 83900000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Land And Improvements: 55330900000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Land And Improvements: 55330900000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Long Term Capital Lease Obligation: 6216300000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 6216300000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Long Term Debt: 447900000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 447900000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 6664200000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 6664200000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Long Term Debt Issuance: 83900000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Long Term Debt Payments: -6574200000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Long Term Equity Investment: 735600000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Long Term Equity Investment: 735600000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Long Term Provisions: 2364500000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 2364500000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Machinery Furniture Equipment: 26628400000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Machinery Furniture Equipment: 26628400000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Minority Interest: 124989200000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Minority Interest: 124989200000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Minority Interests: -9089000000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Minority Interests: -272800000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Net Business Purchase And Sale: -66208800000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Net Common Stock Issuance: 0.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: 2837800000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Net Income: 47281800000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Net Income: 18301500000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Net Income Common Stockholders: 47281800000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 18301500000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Net Income Continuous Operations: 56370800000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 18574300000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 47281800000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 18301500000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 47281800000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 18301500000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Net Income From Continuing Operations: 32987700000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Net Income Including Noncontrolling Interests: 56370800000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 18574300000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Net Interest Income: 3131400000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Net Interest Income: -208000000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Net Investment Purchase And Sale: 42684900000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Net Issuance Payments Of Debt: -6490300000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Net Long Term Debt Issuance: -6490300000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Net Non Operating Interest Income Expense: 3131400000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -208000000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Net Other Investing Changes: 400000000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Net PPE: 537509300000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Net PPE: 537509300000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Net PPE Purchase And Sale: -59557100000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Net Tangible Assets: 446750000000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 446750000000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Revenue: 1525400000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Revenue: 1525400000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Assets: 326600000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 326600000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Liabilities: 34663300000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 34663300000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Non Current Prepaid Assets: 24631500000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Non Current Prepaid Assets: 24631500000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Normalized EBITDA: 73614700000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 17041700000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Normalized Income: 48893880000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Normalized Income: 18916560000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Operating Cash Flow: 53615300000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Operating Income: 30938900000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Operating Income: 4101800000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Operating Revenue: 399694000000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Operating Revenue: 108916800000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Ordinary Shares Number: 2471823478.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 2471823478.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Other Current Assets: 172100000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 172100000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Other Current Liabilities: 9233000000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 9233000000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Other Equity Interest: 153000000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 153000000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Other Intangible Assets: 11268000000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 11268000000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Other Inventories: 13365600000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Other Inventories: 13365600000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Other Non Cash Items: -1394300000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Other Non Current Assets: 30521400000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 30521400000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Other Non Current Liabilities: 1525400000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 1525400000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Other Non Operating Income Expenses: 2277900000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 2338900000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Other Operating Expenses: 120872200000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 44021400000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Other Payable: 52509000000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Other Payable: 52509000000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Other Properties: 353747800000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Other Properties: 353747800000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Other Receivables: 16290200000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Other Receivables: 16290200000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Other Short Term Investments: 323600000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 323600000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Other Special Charges: 3384800000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Other Special Charges: 1025100000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Payables: 100419800000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Payables: 100419800000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 2590400000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 2590400000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Prepaid Assets: 24844900000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 24844900000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Pretax Income: 32987700000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Pretax Income: 5281300000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Properties: 85767300000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Properties: 85767300000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Provisionand Write Offof Assets: 362600000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Purchase Of Business: -66208800000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Purchase Of Investment: 0.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Purchase Of PPE: -63443300000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Raw Materials: 17345700000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Raw Materials: 17345700000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Reconciled Cost Of Revenue: 91097700000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 20046500000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Reconciled Depreciation: 35704100000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 10527300000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Rent And Landing Fees: 1827000000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Rent Expense Supplemental: 1827000000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Repayment Of Debt: -6574200000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Restricted Cash: 515100000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Restricted Cash: 515100000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Retained Earnings: 188866400000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Retained Earnings: 188866400000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Sale Of Business: 0.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Sale Of Investment: 42684900000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Sale Of PPE: 3886200000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Selling And Marketing Expense: 104572800000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Selling And Marketing Expense: 26498700000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Selling General And Administration: 107548200000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Selling General And Administration: 26498700000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Share Issued: 2471823478.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Share Issued: 2471823478.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Special Income Charges: -3384800000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Special Income Charges: -1025100000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Stockholders Equity: 593473200000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 593473200000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Tangible Book Value: 446750000000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 446750000000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Tax Effect Of Unusual Items: -1074720000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: -410040000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Tax Provision: -23383100000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Tax Provision: -13293000000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Tax Rate For Calcs: 0.40
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.40
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Taxes Receivable: 20717300000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Taxes Receivable: 20717300000.00
AMBUJACEM.NS cash_flow (annual, 2026-03-31) — Taxes Refund Paid: 2822100000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Total Assets: 896066000000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Total Assets: 896066000000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Total Capitalization: 593921100000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 593921100000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Total Debt: 8659300000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Total Debt: 8659300000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Total Equity Gross Minority Interest: 718462400000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 718462400000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Total Expenses: 368755100000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Total Expenses: 104815000000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Total Liabilities Net Minority Interest: 177603600000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 177603600000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 758906200000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 758906200000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 46641200000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 46641200000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Total Tax Payable: 5629900000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 5629900000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Total Unusual Items: -2686800000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items: -1025100000.00
AMBUJACEM.NS income_statement (annual, 2026-03-31) — Total Unusual Items Excluding Goodwill: -2686800000.00
AMBUJACEM.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: -1025100000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Tradeand Other Payables Non Current: 1423800000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Tradeand Other Payables Non Current: 1423800000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Treasury Shares Number: 0.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Treasury Shares Number: 0.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Work In Process: 9174500000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Work In Process: 9174500000.00
AMBUJACEM.NS balance_sheet (annual, 2026-03-31) — Working Capital: 6196900000.00
AMBUJACEM.NS balance_sheet (quarterly, 2026-03-31) — Working Capital: 6196900000.00
AMC cash_flow (annual, 2021-12-31) — Cash Dividends Paid: 0.00
AMC cash_flow (annual, 2021-12-31) — Common Stock Dividend Paid: 0.00
AMC balance_sheet (annual, 2021-12-31) — Financial Assets: 0.00